AbbVie Inc (ABBV)vsBeyondSpring Inc (BYSI)
ABBV
AbbVie Inc
$263.78
-0.02%
HEALTHCARE · Cap: $454.36B
BYSI
BeyondSpring Inc
$0.75
+5.78%
HEALTHCARE · Cap: $31.53M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 3431989% more annual revenue ($64.39B vs $1.88M). ABBV leads profitability with a 9.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
BYSI
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$263.78
$111.62 premium
Margin of Safety
+89.6%
Fair Value
$13.63
Current Price
$0.75
$12.88 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : BYSI
The strongest argument for BYSI centers on Debt/Equity. Revenue growth of 14.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : BYSI
The primary concerns for BYSI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV carries more volatility with a beta of 0.28 — expect wider price swings.
BYSI is growing revenue faster at 14.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 20/100) and 10.2% revenue growth. BYSI offers better value entry with a 89.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
BeyondSpring Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?